Antifungal susceptibility testing of Aspergillus species complex in the Clinical Laboratory: how to do it, when to do it, and how to interpret it

Main Article Content

Esther Manso *
Claudio Farina
Stefano Andreoni
Elisabetta Blasi
Marco Conte
Paolo Fazii
Gianluigi Lombardi
Silvana Sanna
(*) Corresponding Author:
Esther Manso | e.manso@ospedaliriuniti.marche.it

Abstract

The emergence of drug resistance in fungal pathogens has a profound impact on human health given limited number of antifungal drugs. Antifungal resistance in Aspergillus spp. infection can be encountered in the antifungal drug-exposed patient due to selection of intrinsically resistant species or isolates with acquired resistance belonging to species that are normally susceptible. Resistance to triazoles is not common in Aspergillus spp., however, triazole resistance in A. fumigatus appears to be increasing in several European countries in recent years and can be clinically relevant. The Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing have developed breakpoints and epidemiological cutoff values that are now established for Aspergillus spp. Clinical microbiology laboratories will be employed commercial susceptibility assays, rather than reference broth microdilution methods and comparative studies are particularly important.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)